Starting Neurohormonal Antagonists in Patients with Acute Heart Failure with Mid-Range and Preserved Ejection Fraction

Abstract Background The clinical benefits of neurohormonal antagonist in patients with heart failure (HF) mid-range and preserved ejection fraction (HFmrEF HFpEF) were uncertain. This study aimed to evaluate the prognostic effect starting angiotensin-converting enzyme inhibitors (ACE-I) / angiotensin II receptor blockers (ARB) β-blocker during HF hospitalization these patients. Methods We analyzed 858 consecutive HFmrEF (EF:40–49%) or HFpEF (EF≥50%), who hospitalized for acute decompensated HF, discharged alive, not taking ACE-I/ARB β-blockers at admission. population was classified into four groups according status prescription discharge: no (N=342, 39.9%), only (N=128, 14.9%), (N=189, 22.0%), both (N=199, 23.2%) groups. primary outcome measure a composite all-cause death hospitalization. Results cumulative 1-year incidence 41.2% group, 34.0% 28.6% 16.4% group (P<0.001). Compared associated significantly lower risk (HR: 0.59, 95% CI: 0.38–0.91, P=0.02). Conclusions In HFpEF, reduced compared β-blocker. Funding Acknowledgement Type funding sources: None.